NASDAQ · Biotechnology

CAMP4 Therapeutics Corporation (CAMP) Stock

$3.30 -2.65% NASDAQ: CAMP Healthcare

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon.

Valuation

MetricValue
Price$3.30
Market Cap$207.09M
P/E Ratio-1.55
P/B Ratio-288.39
P/S Ratio51.35
EPS (TTM)$0.00
52-Week High$7.75
52-Week Low$2.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-314.08%
ROA-114.79%
ROCE-70.52%
Gross Margin-1766.67%
Operating Margin-1733.33%
Net Margin-21.94%
Debt/Equity-3.42
Current Ratio7.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$296.0M$295.0M$0$1.0M$3.0M
Operating Profit$-13.0M$-25.0M$-52.0M$-53.0M$-52.0M
Net Profit$-28.0M$-32.0M$-49.0M$-52.0M$-80.0M
EPS$0.00$-0.90$-4.07$-2.66$-2.65
Op Margin-4.5%-8.4%-14822.6%-8142.3%-1488.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$402.0M$103.0M$55.0M$78.0M$118.0M
Total Liabilities$322.0M$180.0M$179.0M$15.0M$70.0M
Cash$91.0M$83.0M$38.0M$64.0M$110.0M
Borrowings$209.0M$12.0M$12.0M$9.0M$2.0M

Latest News

Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones? Insider Monkey · Jul 2, 2026 X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors GlobeNewswire · Jul 1, 2026 CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jun 19, 2026 Sector Update: Healthcare Stocks Ease Late Afternoon MT Newswires · Jun 16, 2026 Sector Update: Healthcare MT Newswires · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-39.0M$-44.0M$-46.0M$-30.0M
Investing Cash Flow$-21.0M$-8.0M$-1.0M$-1.0M$-1.0M
Financing Cash Flow$-3.0M$100.0M$0$72.0M$15.0M
Net Cash Flow$-15.0M$83.0M$-45.0M$26.0M$46.0M
Free Cash Flow$-18.0M$-43.0M$-45.0M$-46.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-1.76
FCF Yield-13.50%
Quick Ratio4.70
Interest Coverage—
Return 1Y204.17%
Return 3Y—
Return 5Y—

Ownership

Insiders Held13.07%
Institutions Held86.72%
Institutions Float Held99.76%
Institutional HolderSharesReport Date
Janus Henderson Group PLC6,307,6362026-03-31
5AM Venture Management, LLC5,869,0912026-03-31
FMR, LLC4,933,4322026-03-31
Vivo Capital, LLC4,246,5682026-03-31
Balyasny Asset Management LP2,632,4372026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRVAcrivon Therapeutics, Inc. $1.73 -1.70% -1.12 $74.14M 0.00%
ALXOALX Oncology Holdings Inc. $1.17 -1.68% -1.08 $161.78M 0.00%
ATYRaTyr Pharma, Inc. $0.17 -2.88% -0.46 $16.19M 0.00%
BMEABiomea Fusion, Inc. $0.60 +2.58% -2.56 $43.39M 0.00%
HYFTMindWalk Holdings Corp. $1.16 -3.33% -5.23 $54.65M 0.00%

About CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

CAMP4 Therapeutics Corporation is led by CEO Joshua Mandel-Brehm, employs 55 people, headquartered in US, publicly traded since 2024.

CAMP4 Therapeutics Corporation (CAMP) stock trades at $3.30 with a market capitalization of $207.09M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.55, reflecting a net loss over the last twelve months, a negative price-to-book of -288.39, reflecting negative shareholders' equity, price-to-sales of 51.35. Over the past 52 weeks the stock has ranged between $2.90 and $7.75, and currently trades 57.4% below its 52-week high.

On profitability, CAMP4 Therapeutics Corporation generates a return on equity (ROE) of -314.08% (not meaningful, as shareholders' equity is negative), return on capital employed of -70.52%, an operating margin of -1733.33%, a net profit margin of -21.94%.

Official website: www.camp4tx.com

CAMP4 Therapeutics Corporation by the numbers, 2016–2025

Between 2016 and 2025 CAMP4 Therapeutics Corporation reported revenue of $351.0M rising to $3.0M, a change of -99.1% across 10 years. Compounded, revenue has grown -60.4% a year over five years, -78.3% over three, 200.0% over the last twelve months. Net profit fell to $-80.0M.

Operating margin went from 0.4% in 2016 to -1488.3% in 2025, a fall of 1488.7 percentage points. The most recent net margin is -21.94%. On a trailing twelve-month basis to Jun '26, revenue is $4.0M and net profit $-107.0M.

Borrowings fell from $147.0M to $2.0M, cash on hand is $87.0M, cash from operations was $-30.0M in the latest year, positive in 5 of the last 10.

Return on equity has averaged -40.7% over five years, and was -166.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

CAMP4 Therapeutics Corporation (CAMP) — frequently asked questions

What is CAMP4 Therapeutics Corporation (CAMP) stock price today?

CAMP4 Therapeutics Corporation (CAMP) is currently trading at $3.30, down 2.65% today.

What is CAMP P/E ratio?

CAMP4 Therapeutics Corporation's P/E ratio is -1.55. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CAMP return on equity (ROE)?

CAMP4 Therapeutics Corporation's return on equity (ROE) is -314.08%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is CAMP4 Therapeutics Corporation's market cap?

CAMP4 Therapeutics Corporation has a market capitalization of $207.09M.

Does CAMP pay a dividend?

CAMP4 Therapeutics Corporation is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does CAMP carry?

CAMP4 Therapeutics Corporation has a debt-to-equity ratio of -3.42. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is CAMP's profit margin?

CAMP4 Therapeutics Corporation reports a net profit margin of -21.94% — the share of revenue left after every cost, including tax and interest.

What sector is CAMP in?

CAMP4 Therapeutics Corporation is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is CAMP listed on?

CAMP4 Therapeutics Corporation trades on NASDAQ under the ticker CAMP.

What is CAMP's 52-week range?

Over the last year CAMP4 Therapeutics Corporation has traded between $2.90 and $7.75.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens CAMP currently matches

On the figures above, CAMP4 Therapeutics Corporation passes the filters for 4 of our ready-made screens, among them Penny Stocks, Stocks Under $5, Stocks Under $10. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksStocks Under $5Stocks Under $10Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.